Prenatal Medicine

Gene therapy administered in utero cannot overcome postnatal immune response

Published in Gene Therapy Weekly, August 29th, 2002

by Sonia Nichols, senior medical writer - Animal model experiments suggest that administering gene therapy to fetuses while they are in the uterus does not mitigate their developing an immune response to the same therapy later on.

The use of virus-mediated gene transfer in gene therapy is becoming increasingly popular. However, the competent immune system often recognizes the therapy as being foreign and incapacitates transgene delivery and expression through normal immune response mechanisms.

Scientists have theorized that delivering such therapies before the immune system fully develops, that is, to a growing fetus, might defeat that problem. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-08-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry